Voltalin D

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Voltalin D

Quick Facts

Property Description
Active Ingredient Diclofenac
Form Oral Tablet (often enteric-coated)
Pharmacological Class Non-steroidal Anti-inflammatory Drug (NSAID)
Origin Synthetic Compound (Phenylacetic Acid Derivative)
General Purpose Relief from Pain, Inflammation, and Fever

What is Voltalin D? Definition and Pharmacological Type

Voltalin D is a pharmaceutical product containing the active ingredient Diclofenac, which is classified as a Non-steroidal Anti-inflammatory Drug (NSAID). This designation identifies its role in managing symptomatic relief related to inflammatory processes. Chemically, Diclofenac is a synthetic compound derived from Phenylacetic acid. Voltalin D is positioned as an oral medication intended for individuals requiring systemic relief, such as those experiencing musculoskeletal discomfort, and is typically distributed as a Prescription-Only Medicine (POM) in many regions.

Composition, Formulation, and Origin

The medication is a single-ingredient product, containing only Diclofenac, often formulated as the sodium or potassium salt. Voltalin D is commonly supplied as an oral dosage form, typically a tablet. A key feature of this brand's formulation is the frequent use of an enteric coating. This specialized layer is designed to protect the active substance from stomach acidity, enabling its release and optimal absorption in the small intestine. This formulation technique is used to improve drug handling in the digestive system, ensuring the medication achieves a reliable **systemic effect.

General Purpose: Analgesic and Anti-inflammatory Role

The general purpose of Voltalin D is rooted in its combined ability to act as an effective analgesic (pain reliever) and a powerful anti-inflammatory agent. Its therapeutic role is to provide relief from symptoms such as pain, swelling, and elevated body temperature (pyrexia). This is achieved by interfering with the biological pathway that produces prostaglandins, the key chemical mediators responsible for driving inflammation and pain signals. Therefore, its principal function is to suppress these processes, contributing to overall functional relief.

Regulatory References

  1. NIH: Diclofenac - StatPearls

What side effects are possible with Voltalin D?

Possible Side Effects and Safety Information

The safety profile for Voltalin D (Diclofenac) is documented in official regulatory labeling and is characterized by a specific set of adverse reactions classified by frequency and affected body system. As a non-steroidal anti-inflammatory drug (NSAID), its use is associated with a class-wide risk of serious events.


Frequency-Classified Adverse Reactions

The most common side effects (ge 1/100 to < 1/10) reported in regulatory documents primarily affect the Gastrointestinal and Nervous System domains. These include dyspepsia, nausea, diarrhea, abdominal pain, headache, and dizziness, along with elevations in liver enzymes.

Rare adverse reactions (ge 1/10,000 to < 1/1,000) documented in official sources include gastrointestinal bleeding or ulceration, hepatitis, and severe hypersensitivity reactions.


Serious Safety Considerations

Official labeling contains mandatory warnings regarding the potential for serious events. These include an increased risk of Cardiovascular Thrombotic Events such as myocardial infarction (heart attack) and stroke. This risk may increase with the duration of use and is more consistently observed at higher doses.

Serious Gastrointestinal Adverse Events like bleeding, ulceration, or perforation are also documented. These events can occur at any time during treatment and may happen without warning symptoms.


Safety Restrictions and Special Populations

Safety limitations are defined for certain patient groups. Use is officially restricted or contraindicated in individuals with established severe heart failure (NYHA Class II-IV), specific ischemic heart disease, and severe hepatic or renal impairment. Furthermore, the medicine is contraindicated for treating pain immediately following Coronary Artery Bypass Graft (CABG) surgery, and in patients with a history of allergic reactions to other NSAIDs or aspirin.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Voltalin D (Diclofenac) is defined by documented clinical manifestations that primarily affect the gastrointestinal (GI) and Central Nervous System (CNS). Officially listed manifestations include common GI complaints such as nausea, vomiting, abdominal pain, and diarrhea, along with CNS effects like headache, drowsiness, dizziness, and confusion. More severe CNS effects, such as seizures and coma, are recorded outcomes associated with very high exposures, and are considered potentially life-threatening.

The official regulatory profile identifies severe systemic toxicity, highlighting outcomes that include acute renal failure, severe GI bleeding, and metabolic acidosis. Given these risks, and the explicit regulatory statement that no specific antidote is known for Diclofenac toxicity, the mandated action is to seek immediate medical help right away upon any suspicion of overdose.

Management is limited to symptomatic and supportive treatment. Regulator-described procedures for potential overdose include the consideration of gastric decontamination and the administration of activated charcoal. Furthermore, official guidance notes that elderly patients are at greater risk for serious gastrointestinal events, and individuals with asthma may be more susceptible to respiratory effects following an overdose event.

Therapeutic Uses of Voltalin D

What Voltalin D Treats: Main Uses and Benefits

The medication is applied across domains where additional symptomatic support is needed, primarily focusing on pain and inflammation. Its role is relevant when supportive symptom management is appropriate across therapeutic areas where heightened physiological discomfort is present. This includes its role in managing pain, tenderness, swelling, and stiffness in joints.

Voltalin D is relevant in clinical settings that involve acute or unstable symptom patterns, such as pain and inflammation following minor injuries or specific surgical procedures. It is commonly used for managing chronic conditions like rheumatoid arthritis and osteoarthritis, as well as the recurrent discomfort associated with primary dysmenorrhea (menstrual pain). This provides support that helps ease the overall symptom burden.

“The therapeutic approach is relevant for easing symptoms that interfere with patient comfort and may affect functional stability.”


Therapeutic Summary for Symptom Management

Domain Conditions Addressed Primary Benefit
Rheumatology Chronic arthritis, Degenerative joint pain May assist with maintaining functional stability and easing stiffness.
Acute Trauma Minor strains, Post-operative inflammation Provides supportive relief during acute pain and swelling episodes.
Gynecology Primary dysmenorrhea Helps patients cope more steadily with disruptive episodic pain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility profile for Voltalin D (Diclofenac) is strictly governed by regulatory classifications that define permissible and prohibited populations.

The medicine is contraindicated for individuals with known hypersensitivity to diclofenac or any other Non-steroidal Anti-inflammatory Drug (NSAID), including a history of aspirin-sensitive asthma. Absolute prohibition also applies to pregnant women 30 weeks gestation and later, and patients receiving treatment for perioperative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Use must be avoided in patients with advanced renal disease, severe heart failure, or a history of recent myocardial infarction, unless a clinician determines that the benefits significantly outweigh the established risks. Caution is mandatory for the elderly and for patients with a prior history of peptic ulcer disease or gastrointestinal bleeding.

Regarding age, the safety and effectiveness of most oral formulations are not established for children younger than 12 years of age. Women who are 20 to 30 weeks pregnant may use the drug, but only at the lowest effective dose for the shortest duration.

What should I know about interactions with other medicines?

Voltalin D, an anti-inflammatory drug, must be used with caution due to several clinically significant interactions. The co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including aspirin (in analgesic doses), or corticosteroids is generally not recommended as it significantly increases the risk of serious gastrointestinal bleeding and ulceration.

Anticoagulants and Agents Affecting Hemostasis

Concomitant use with anticoagulants (e.g., warfarin) or anti-platelet agents increases the risk of serious bleeding. Monitoring of coagulation parameters is essential. The risk of bleeding is also heightened when combined with SSRIs or SNRIs.

Antihypertensive and Diuretic Agents

The drug may diminish the blood pressure-lowering effect of ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and Beta-blockers. It can also reduce the natriuretic (salt and water excretion) effect of diuretics (e.g., furosemide, thiazides). Combining these requires regular monitoring of blood pressure and kidney function, especially in the elderly or those with pre-existing renal impairment.

Other Medications

Voltalin D can increase the serum concentrations of lithium, digoxin, and methotrexate, potentially leading to toxicity. Co-administration with CYP2C9 inhibitors (e.g., voriconazole) increases Voltalin D's plasma concentrations, necessitating a dose reduction of Voltalin D. It is also advised to monitor for nephrotoxicity when used with cyclosporine or tacrolimus.

Mechanism of Action

Core Mechanism: Inhibiting Prostaglandin Production

This domain covers the drug's primary action: non-selective inhibition of Cyclooxygenase (COX) enzymes, which blocks the conversion of arachidonic acid into pro-inflammatory and pain-sensitizing prostaglandins. This molecular blockade is the core step that results in the physiological consequences of decreased tissue edema and erythema, elevated pain threshold, and lowered systemic body temperature.


Modulating Nociception and Central Pathways

Beyond COX inhibition, the mechanism involves multimodal actions that influence nociceptive signaling pathways, including potential interactions with substances like Substance P and the nitric oxide pathway. This complementary activity modifies nociceptive signaling and regulates the thermal set point in the hypothalamus, resulting in altered pain perception and temperature modulation.


Physiological Trade-offs of Non-Selective Action

This domain explains the biological consequences of the drug's non-selective action on both COX-1 and COX-2. Inhibition affects both inflammatory prostanoids and those that mediate constitutive physiological processes in tissue such as the gastrointestinal tract and renal system.

Dosage and Administration Information

The administration of Voltalin D (Diclofenac Oral Tablet) involves specific protocols regarding the route, dosage, and timing. The medication is intended for oral use (swallowing) and is characterized by the principle of using the lowest effective dose for the shortest necessary duration.

Standard Dosing and Frequency

The dosage regimen varies based on the formulation and condition. Delayed-Release (DR) tablets are typically dosed in the range of 100 mg to 150 mg per day in divided doses (e.g., two or three times daily). The Extended-Release (ER) 100 mg tablets follow a once-per-day schedule. Maximum daily doses are defined and should not be exceeded.

Administration Specifics

Administration requires the tablets to be swallowed whole with a full glass of water. The delayed-release and extended-release tablets must not be crushed, split, or chewed, as this action compromises the specialized coating designed to control drug release. The medicine may be taken with or without food, although taking it with food or milk may help mitigate gastrointestinal irritation. For older adults, treatment is initiated using the lowest effective dose. If a dose is missed, the patient should skip the missed dose and take the next scheduled dose; the practice is to never double the dose.

Recent Clinical Evidence

Research evidence / Overview of Studies for Voltalin D

Evidence Base for Chronic Inflammatory Conditions

Research examined Voltalin D in studies exploring outcomes related to chronic inflammatory joint conditions, such as Rheumatoid Arthritis and Osteoarthritis. These studies utilized rigorous study types, including Randomized Controlled Trials (RCTs), where patient groups were compared under strict conditions, and large-scale Systematic Reviews that combine the results of multiple trials. The evidence base for this indication is assigned a level of High, based on the consistency of the study designs used.

These studies were designed to evaluate how symptoms evolved in adult populations experiencing these conditions. Researchers monitored outcomes related to physical discomfort, assessing changes in pain intensity using standardized patient surveys. Trials also examined outcomes related to systemic or functional imbalance, including measurement of joint tenderness, stiffness, and overall functional stability scores. However, the majority of dedicated investigative trials for these chronic uses are conducted over a short-to-intermediate duration, typically spanning a few weeks up to 12 months. This means that long-term outcomes are not fully established by prospective, randomized research, and follow-up durations were limited.

Evidence for Acute Pain and Episodic Relief

The evidence landscape for Voltalin D in research scenarios exploring short-term symptomatic patterns, such as those associated with Primary Dysmenorrhea or other mild-to-moderate pain episodes, relies on trials designed to assess rapid symptomatic change. For Primary Dysmenorrhea, research examined outcomes describing episodic or acute changes, such as measuring acute pain intensity and the time to onset of relief. The evidence for this specific, short-term application is classified as High.

Research Gaps and Areas of Uncertainty

Evidence highlights what is known—and what is still uncertain—about Voltalin D. A primary limitation is the limited information for long-term outcomes from highly controlled clinical trials, especially concerning the maintenance of functional stability over many years. Furthermore, subgroup findings are uncertain when moving beyond the core adult populations studied. Research describes group patterns, and findings help contextualize the evidence landscape but do not provide individual predictions.

Key Studies & References

  1. Dysmenorrhea, a narrative review of therapeutic options (Systematic Review including Diclofenac)

Frequently Asked Questions (FAQ)

Common questions about Voltalin D (FAQ)


Q: How quickly should I expect to notice the effects of Voltalin D?

Research examining acute pain episodes indicates that the initial onset of relief may be expected within 30 minutes to one hour after taking the medicine. Official documents note that this timing may vary based on the specific formulation used.


Q: How long does one dose of Voltalin D typically last in the body?

Official product information relates the duration of the medicine's effect to the formulation type (e.g., extended-release or standard). Although the drug is rapidly cleared from the bloodstream, the clinical effects of reducing pain and inflammation may last long enough to support a typical once or twice daily regimen.


Q: Can Voltalin D cause dizziness or affect driving?

Regulatory documents list dizziness and drowsiness as common potential side effects of Voltalin D. Because these effects could potentially impair alertness, official patient counseling information describes the need for care when performing tasks such as driving or operating heavy machinery.


Q: Do I need to avoid any specific foods or drinks while using Voltalin D?

Official labeling generally does not specify foods to avoid. The medicine can be taken with or without food; however, regulatory information suggests taking it with food or milk as a way to mitigate potential stomach irritation.


Q: Can Voltalin D interact with common over-the-counter cold medicines?

Regulatory information generally contraindicates taking Voltalin D with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), which includes common over-the-counter pain and cold medicines. Co-administration of these agents is associated with an elevated risk of serious adverse effects, such as gastrointestinal bleeding, as noted in official documents.


Q: Is Voltalin D safe for long-term use, or is it only for short periods?

Official warnings state that this class of medicine is intended for use at the lowest effective dose for the shortest duration possible. Regulatory documents note that the risk of serious adverse cardiovascular and gastrointestinal events is associated with the duration of use.


Q: Does Voltalin D affect blood pressure?

Official documents describe the potential for this medicine to lead to new onset or worsening of hypertension (high blood pressure). Regulatory guidance therefore requires that blood pressure monitoring be considered for individuals using this medication.


Q: Can people who are pregnant or breastfeeding use Voltalin D?

The use of Voltalin D is strictly contraindicated from 30 weeks gestation onward. For pregnancy between 20 and 30 weeks, official guidance restricts use to the lowest effective dose for the shortest duration, only when deemed medically necessary. The active ingredient also passes into breast milk.


Q: Has Voltalin D been studied in children or adolescents?

According to official labeling, the safety and effectiveness of the oral tablet formulation of Voltalin D are not established for most children and adolescents, particularly those under the age of 12 years.


Q: Are there any specific activities to avoid while using this medication?

Official warnings are provided because the drug commonly causes side effects such as dizziness and visual disturbances. Because these effects may impair concentration and coordination, regulatory information describes a need for care when engaging in activities that require high alertness, such as driving or operating heavy machinery.


Q: Is it common for doctors to start patients on a low dose of Voltalin D?

Regulatory guidance defines the principle that treatment should be initiated at the lowest effective dose for all patients. This is a core directive intended to minimize potential risks, and it is particularly noted in guidance related to older adults.


Q: Is there a maximum time frame for how long I can use Voltalin D?

Official warnings emphasize the constraint that the medicine is required for use for the shortest duration possible to reduce the risk of serious side effects. Continuous long-term use is associated with increased safety risks, as documented in official warnings.


Q: Is the effect of Voltalin D immediately noticeable or does it build up over time?

Research for acute conditions has examined the time to onset of relief, which is sometimes noticeable within the first hour. When the medicine is used for chronic inflammatory conditions, official information indicates that the full therapeutic benefit may be observed after several days of consistent administration.


Q: What is the typical experience of people starting Voltalin D?

When initiating treatment, the typical experience may include common but mild gastrointestinal or nervous system effects. Regulatory documents list common side effects such as nausea, indigestion (dyspepsia), diarrhea, and headache. Many people, however, may experience no immediate adverse effects upon starting.


Q: What kind of pain is Voltalin D generally most effective for?

Voltalin D is officially indicated for the management of pain and inflammation associated with chronic inflammatory joint conditions, such as osteoarthritis and rheumatoid arthritis. It is also indicated for acute pain episodes, specifically primary dysmenorrhea (menstrual pain).


Q: Is Voltalin D the same type of medicine as regular Voltalin?

Voltalin D is a brand name for the active ingredient Diclofenac, which is classified as an NSAID. While the formulation may differ from other diclofenac products—for example, by having a specialized coating—the core mechanism and primary action remain the same.


Q: Can Voltalin D interact with supplements like vitamins or herbal products?

Regulatory documents include warnings against combining this medicine with any products that may increase the risk of bleeding or affect drug metabolism. This includes herbal supplements like Ginkgo biloba or St. John's wort, which have been associated with potential interaction risks in official guidance.


Q: Is Voltalin D known to cause weight gain or loss?

Official documentation lists fluid retention and edema (swelling) as recognized side effects of this class of medicine. These conditions can result in a change in body weight, and monitoring for these effects is a regulatory consideration.


Q: What are the signs of an allergic reaction to Voltalin D?

Official labeling describes severe hypersensitivity reactions that can manifest as symptoms such as hives, swelling of the face or throat, and difficulty breathing. Regulatory guidance states that the presence of these signs necessitates seeking immediate medical attention.


Q: How long does Voltalin D stay in the system after stopping use?

The primary active compound has a short biological half-life of approximately 1 to 2 hours. This means the compound is rapidly eliminated from the bloodstream after the last dose is administered.


Q: Are there different strengths of Voltalin D available?

Yes, regulatory documents list different available strengths for the oral tablets. These typically include strengths such as 25 mg, 50 mg, and 75 mg for the delayed-release formulation, and 100 mg for the extended-release formulation.


Q: Where can I find official information about Voltalin D?

The full, authorized regulatory information for this drug is publicly available through governmental bodies. You can typically find official documents such as the DailyMed record or the FDA Patient Medication Guide provided by regulatory agencies.


Q: What is the difference between Voltalin D and generic diclofenac?

Official regulatory documents confirm that generic diclofenac is bioequivalent to the brand name Voltalin D, meaning they deliver the same amount of active ingredient to the bloodstream. Any differences typically relate to the inactive ingredients and the specific formulation used by the manufacturer.


Q: Is Voltalin D addictive or habit-forming?

Voltalin D is classified as a Non-Steroidal Anti-inflammatory Drug (NSAID) and is not listed as a controlled substance. For this reason, official labeling does not contain warnings about the potential for dependence or addiction.


Q: Can Voltalin D be used for nerve pain?

Voltalin D is officially indicated for treating pain and inflammation associated with specific conditions such as arthritis and dysmenorrhea. It is not officially indicated in regulatory documents for the treatment of neuropathic pain (nerve pain).


Q: What should I do if a side effect seems mild but doesn't go away?

Official patient guides advise that seeking contact with a healthcare provider is the appropriate step if a side effect is bothersome, worsens, or persists throughout the treatment period.


Q: Does alcohol change how Voltalin D works?

Regulatory warnings regarding alcohol consumption while using this medicine state that co-administration is not recommended. Taking the medicine with alcohol is associated with an increased risk of gastrointestinal bleeding and potential increased side effects related to liver function.


Q: Can Voltalin D interact with diabetes medications?

Official documents list potential interactions with certain sulfonylurea antidiabetic agents. Co-administration may affect blood sugar levels, and regulatory guidance requires that blood glucose levels be monitored when these medicines are used simultaneously.


Q: Does taking Voltalin D affect sleep?

Official documentation notes that less common side effects can affect the central nervous system. These may include insomnia (difficulty sleeping) or nightmares.

How should Voltalin D be stored and disposed of?

How to Store and Dispose of Voltaren D

To maintain the stability and quality of Voltaren D (diclofenac sodium dispersible tablets), storage must adhere strictly to regulatory conditions. The medicine should be stored at controlled room temperature, typically 20 C to 25 C, and kept from freezing or exposure to excessive heat.

Required Storage and Handling

Condition Regulatory Requirement
Temperature Controlled room temperature; keep from freezing
Protection Protect from excessive moisture and heat
Packaging Keep in a tight container and use before the expiry date

All medicines, including Voltaren D, must be stored out of the sight and reach of children to prevent accidental ingestion. Unused or expired tablets should not be disposed of in wastewater or standard household trash; official disposal instructions from a healthcare professional or pharmacist must be followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Voltalin D found in:

A-Z Index: